Wells Fargo gives Atrium Therapeutics a Strong Buy rating on its rare cardiomyopathy programs

Wells Fargo analyst initiates coverage on Atrium Therapeutics with Overweight rating and $25 price target, highlighting big potential in RNA therapies for rare genetic heart diseases with no current treatments.